1. Nowell, P.C., The clonal evolution of tumor cell populations.
Science, 1976. 194(4260): p. 23-28.
2.Bourguignon, L.Y., Matrix hyaluronan-CD44 interaction
activates MicroRNA and LncRNA signaling associated with
chemoresistance, invasion, and tumor progression. Frontiers in
oncology, 2019. 9: p. 492.
3.Futreal, P.A., et al., A census of human cancer genes. Nature
reviews cancer, 2004. 4(3): p. 177-183.
4.Cancer Types. Available from: https://www.cancer.gov/types.
5.Strausberg, R.L., A.J. Simpson, and R. Wooster, Sequence-based
cancer genomics: progress, lessons and opportunities. Nature
Reviews Genetics, 2003. 4(6): p. 409-418.
6.Wilson, J.M.G., G. Jungner, and W.H. Organization, Principles and
practice of screening for disease. 1968.
7.Rossi, A., et al., The impact of personalized medicine on survival:
comparisons of results in metastatic breast, colorectal and non-
small-cell lung cancers. Cancer treatment reviews, 2014. 40(4):
p. 485-494.
8.Jackson, S.E. and J.D. Chester, Personalised cancer medicine.
International journal of cancer, 2015. 137(2): p. 262-266.
9.Schilsky, R.L., Personalized medicine in oncology: the future is
now. Nature reviews Drug discovery, 2010. 9(5): p. 363-366.
10.Meadows, M., Genomics and personalized medicine. FDA
consumer, 2005. 39(6): p. 12-17.
11.Rahman, M.M., Personalized Medicine in Cancer. Journal of
Bangladesh College of Physicians and Surgeons, 2014. 32(3): p.
153-163.
12.Medicine Tailored Just for You, in Newsweek. June 10, 2005.
13.Science, P.s.C.o.A.o. and Technology, Priorities for personalized
medicine. 2008, Executive Office of the President Washington DC14.Stricker, T., D.V. Catenacci, and T.Y. Seiwert. Molecular profiling
of cancer—the future of personalized cancer medicine: a primer
on cancer biology and the tools necessary to bring molecular
testing to the clinic. in Seminars in oncology. 2011. Elsevier.
15.Verma, M., Personalized medicine and cancer. Journal of
personalized medicine, 2012. 2(1): p. 1-14.
16.Schroth, W., et al., Association between CYP2D6 polymorphisms
and outcomes among women with early stage BCtreated with
tamoxifen. Jama, 2009. 302(13): p. 1429-1436.
17.Zülch, K.J., Brain tumors: their biology and pathology. 2013:
Springer-Verlag.
18.Feng, Y., et al., BCdevelopment and progression: Risk factors,
cancer stem cells, signaling pathways, genomics, and molecular
pathogenesis. Genes & diseases, 2018. 5(2): p. 77-106.
19.Silva, C.O., et al., Current trends in cancer nanotheranostics:
metallic, polymeric, and lipid-based systems. Pharmaceutics,
2019. 11(1): p. 22.
20.Fackenthal, J.D. and O.I. Olopade, BCrisk associated with
BRCA1 and BRCA2 in diverse populations. Nature Reviews
Cancer, 2007. 7(12): p. 937-948.
21.Antoniou, A., et al., A comprehensive model for familial
BCincorporating BRCA1, BRCA2 and other genes. British
journal of cancer, 2002. 86(1): p. 76-83.
22.Parmigiani, G., D.A. Berry, and O. Aguilar, Determining carrier
probabilities for breast cancer–susceptibility genes BRCA1 and
BRCA2. The American Journal of Human Genetics, 1998. 62(1):
p. 145-158.
23.Cox, A., et al., A common coding variant in CASP8 is associated
with BCrisk. Nature genetics, 2007. 39(3): p. 352-358.
24.Easton, D.F., et al., Genome-wide association study identifies
novel BCsusceptibility loci. Nature, 2007. 447(7148): p. 1087-
1093.
25.Hunter, D.J., et al., A genome-wide association study identifies
alleles in FGFR2 associated with risk of sporadic postmenopausal
breast cancer. Nature genetics, 2007. 39(7): p. 870-874.
26.Pharoah, P.D., et al., Polygenes, risk prediction, and targeted
prevention of breast cancer. New England Journal of Medicine,
2008. 358(26): p. 2796-2803.
27.Pharoah, P.D.P., et al., Association between common variation in
120 candidate genes and BCrisk. PLoS genetics, 2007. 3(3): p.
e42.
28.Stacey, S.N., et al., Common variants on chromosomes 2q35 and
16q12 confer susceptibility to estrogen receptor–positive breast
cancer. Nature genetics, 2007. 39(7): p. 865-869.
29.Stacey, S.N., et al., Common variants on chromosome 5p12
confer susceptibility to estrogen receptor–positive breast cancer.
Nature genetics, 2008. 40(6): p. 703-706.
30.Hinds, D.A., et al., Whole-genome patterns of common DNA
variation in three human populations. Science, 2005. 307(5712):
p. 1072-1079.
31.Frazer, K., et al., Hardenbol P, Leal SM, et al: A second generation
human haplotype map of over 3.1 million 2 SNPs. Nature, 2007.
449: p. 851-861.
32.de Souza, J.A. and O.I. Olopade. CYP2D6 genotyping and
tamoxifen: an unfinished story in the quest for personalized
medicine. in Seminars in oncology. 2011. Elsevier.
33.Brauch, H., et al., Pharmacogenomics of tamoxifen therapy.
Clinical chemistry, 2009. 55(10): p. 1770-1782.
34.Brauch, H. and V.C. Jordan, Targeting of tamoxifen to enhance
antitumour action for the treatment and prevention of breast
cancer: the ‘personalised’approach? European Journal of Cancer,
2009. 45(13): p. 2274-2283.
35.Hoskins, J.M., L.A. Carey, and H.L. McLeod, CYP2D6 and
tamoxifen: DNA matters in breast cancer. Nature Reviews Cancer,
2009. 9(8): p. 576-586.
36.Schroth, W., et al., CYP2D6 polymorphisms as predictors
of outcome in BCpatients treated with tamoxifen: expanded
polymorphism coverage improves risk stratification. Clinical
Cancer Research, 2010. 16(17): p. 4468-4477.
37.Hatzis, C., et al., A genomic predictor of response and survival
following taxane-anthracycline chemotherapy for invasive breast
cancer. Jama, 2011. 305(18): p. 1873-1881.
38.Arao, T., et al., What can and cannot be done using a microarray
analysis? Treatment stratification and clinical applications in
oncology. Biological and Pharmaceutical Bulletin, 2011. 34(12):
p. 1789-1793.
39.Barginear, M., et al., Increasing tamoxifen dose in BCpatients
based on CYP2D6 genotypes and endoxifen levels: effect on
active metabolite isomers and the antiestrogenic activity score.
Clinical Pharmacology & Therapeutics, 2011. 90(4): p. 605-611.
40.Cronin-Fenton, D.P. and T.L. Lash, Clinical epidemiology and
pharmacology of CYP2D6 inhibition related to BCoutcomes.
Expert review of clinical pharmacology, 2011. 4(3): p. 363-377.
41.Fleeman, N., et al., The clinical effectiveness and cost-
effectiveness of genotyping for CYP2D6 for the management of
women with BCtreated with tamoxifen: a systematic review. 2011.
42.Lu, W.J., et al., The tamoxifen metabolite norendoxifen is a potent
and selective inhibitor of aromatase (CYP19) and a potential
lead compound for novel therapeutic agents. BCresearch and
treatment, 2012. 133(1): p. 99-109.
43.Krijgsman, O., et al., A diagnostic gene profile for molecular
subtyping of BCassociated with treatment response. BCresearch
and treatment, 2012. 133(1): p. 37-47.
44.Kim, C., et al., Estrogen receptor (ESR1) mRNA expression and
benefit from tamoxifen in the treatment and prevention of estrogen
receptor–positive breast cancer. Journal of clinical oncology,
2011. 29(31): p. 4160.
45.Wolff, A.C., et al., American Society of Clinical Oncology/
College of American Pathologists guideline recommendations for
human epidermal growth factor receptor 2 testing in breast cancer.
Archives of pathology & laboratory medicine, 2007. 131(1): p.
18-43.
46.Patani, N., L.A. Martin, and M. Dowsett, Biomarkers for the
clinical management of breast cancer: international perspective.
International journal of cancer, 2013. 133(1): p. 1-13.
47.Anderson, W.F., et al., Estrogen receptor BCphenotypes in
the Surveillance, Epidemiology, and End Results database.
BCresearch and treatment, 2002. 76(1): p. 27-36.
48.Cui, X., et al., Biology of progesterone receptor loss in BCand its
implications for endocrine therapy. Journal of clinical oncology,
2005. 23(30): p. 7721-7735.
49.Rakha, E.A., et al., Biologic and clinical characteristics of
BCwith single hormone receptor–positive phenotype. Journal of
clinical oncology, 2007. 25(30): p. 4772-4778.
50.Horwitz, K.B. and W. McGuire, Estrogen control of progesterone
receptor in human breast cancer. J biol chem, 1978. 253(7): p.
2223-2228.
51.Lee, M., C.S. Lee, and P.H. Tan, Hormone receptor expression in
breast cancer: postanalytical issues. Journal of clinical pathology,
2013. 66(6): p. 478-484.
52.Rivenbark, A.G., S.M. O’Connor, and W.B. Coleman, Molecular
and cellular heterogeneity in breast cancer: challenges for
personalized medicine. The American journal of pathology, 2013.
183(4): p. 1113-1124.
53.Dowsett, M. and A.K. Dunbier, Emerging biomarkers and new
understanding of traditional markers in personalized therapy for
breast cancer. Clinical Cancer Research, 2008. 14(24): p. 8019-
8026.
54.Paik, S., et al., A multigene assay to predict recurrence of
tamoxifen-treated, node-negative breast cancer. New England
Journal of Medicine, 2004. 351(27): p. 2817-2826.
55.Pusztai, L., M. Cristofanilli, and S. Paik. New generation of
molecular prognostic and predictive tests for breast cancer. in
Seminars in oncology. 2007. Elsevier.
56.Sotiriou, C. and M.J. Piccart, Taking gene-expression profiling
to the clinic: when will molecular signatures become relevant to
patient care? Nature reviews cancer, 2007. 7(7): p. 545-553.
57.Hess, K.R., et al., Pharmacogenomic predictor of sensitivity
to preoperative chemotherapy with paclitaxel and fluorouracil,
doxorubicin, and cyclophosphamide in breast cancer. Journal of clinical oncology, 2006. 24(26): p. 4236-4244.
58.Hudis, C.A., Trastuzumab—mechanism of action and use in
clinical practice. New England journal of medicine, 2007. 357(1):
p. 39-51.
59.Citron, M.L., et al., Randomized trial of dose-dense versus
conventionally scheduled and sequential versus concurrent
combination chemotherapy as postoperative adjuvant treatment
of node-positive primary breast cancer: first report of Intergroup
Trial C9741/Cancer and Leukemia Group B Trial 9741. Journal of
clinical oncology, 2003. 21(8): p. 1431-1439.
60.Tan, S.-H., et al., Pharmacogenetics in BCtherapy. Clinical
Cancer Research, 2008. 14(24): p. 8027-8041.
61.Koboldt, D., et al., Comprehensive molecular portraits of human
breast tumours. Nature, 2012. 490(7418): p. 61-70.